KRAS
Entity.
- Evidence
- 415 documents · 167 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 1 Jan 2026, last seen 5 Oct 2026
- Measured
- 14% of mentions say something specific about it; the rest only name it
- As of
- 6 Oct 2026
Where this comes from
- J Thromb Haemost · 2026-10-03 · KRAS Mutation and Venous Thromboembolism Risk in Colorectal Cancer: A Danish Population-Based Cohort Study. (opens the source in a new tab)
- KRAS Mutation Research (Google News) via Google News · 2026-10-02 · Understanding the KRAS Mutation Landscape in Biliary Tract Cancer - CancerNetwork (no link on file)
- Int J Cancer · 2026-10-02 · Spatial Transcriptomic Profiling Reveals a Fibroblast-Associated Extracellular Matrix Niche in KRAS G12C-Mutant Lung Adenocarcinoma Primary Tumors From Patients With Metas… (opens the source in a new tab)
- Fierce Pharma · 2026-10-02 · Fierce Pharma Asia—AZ’s $2B bet on ivonescimab; Novo buys Hengrui GLP-1; Merck doubles down on KRAS (opens the source in a new tab)
- KRAS Mutation Research (Google News) via Google News · 2026-10-02 · FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC - OncLive (no link on file)
- Future Oncol · 2026-10-01 · SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy. (opens the source in a new tab)
- GEN - Genetic Engineering & Biotechnology News · 2026-09-30 · Merck, SciBrunch Launch Up-to-$2.13B Collaboration to Develop Preclinical KRAS-Inhibiting Molecular Glue (opens the source in a new tab)
- Sci Transl Med · 2026-09-30 · FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer. (opens the source in a new tab)
- Endpoints News · 2026-09-29 · Merck licenses a KRAS G12D inhibitor for $400M upfront (opens the source in a new tab)
- Targeted Therapy Oncology (Google News) via Google News · 2026-09-29 · Are KRAS Mutations More Common Than We Think? - Targeted Oncology (no link on file)
- Fierce Biotech · 2026-09-28 · Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D (opens the source in a new tab)
- FDA Oncology (Google News) via Google News · 2026-09-28 · KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 - Finansavisen (no link on file)
What is claimed about it
- Single source: Reported by one source so far.
- FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer. Single source · first reported 30 Sept 2026